UNSPSC 51422434: Hydrocortisone sodium succinate

This classification denotes a therapeutic hydrocortisone with the molecular formula C25H33O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50LQB69S1Z, chemically known as 1,4-butanedioic acid (succinic acid) but more generally known as hydrocortisone sodium succinate, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Hydrocortisone sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02569MIG.

UNSPSC 51422434 Hydrocortisone sodium succinate is a Commodity code nominally identifying a specific pharmaceutical product, but the recent state and local opportunities tagged under it show no direct procurement of hydrocortisone sodium succinate itself. Instead, the opportunities reflect broader pharmaceutical and pharmacy-benefit management activity at the state and county level — naloxone and drug deactivation systems procurement by a Florida county health agency, and a strategic Texas state health commission RFI on direct-to-manufacturer prescription delivery models. The code mismatch suggests either tagging drift in the source database or that the pharmaceutical code serves as a catch-all umbrella for related pharmacy and medication-supply solicitations. State and local buyers under this code span county health departments and state health agencies responsible for pharmacy benefits, employee health plans, and community health initiatives.

Recent activity appears limited to Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, a two-year initial term with one-year renewal option, and response deadline of July 26, 2023 (note: the posted date of June 30, 2026 conflicts with the 2023 response deadline in the source, suggesting data inconsistency). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit managers and group purchasing organizations, designed as exploratory market intelligence before formal RFP issuance. No set-asides or disadvantaged-enterprise designations appear in either opportunity. The code shows sparse recent activity and poor alignment between its nominal pharmaceutical focus and the health-system infrastructure and program-design work actually being solicited.